New CAR-NKT cell therapy uses invariant natural killer T cells (NKT cells). This dual-action therapy increases effectiveness.
Breakthrough Immunotherapy for Pancreatic Cancer Developed by UCLA Scientists
Estimated reading time: 3 minutes
Pancreatic cancer is notoriously difficult to treat, with a dismal five-year survival rate of about 13%. Now, UCLA researchers have developed a promising new immunotherapy for pancreatic cancer that could change patient outcomes significantly. This innovative approach uses engineered immune cells that can be mass-produced and used off-the-shelf, making treatments faster and more affordable.
Novel Immunotherapy for Pancreatic Cancer Shows Remarkable Promise
Current immunotherapies for pancreatic cancer struggle due to the tumor’s dense and protective environment. However, UCLA’s new CAR-NKT cell therapy has overcome these barriers. The therapy uses invariant natural killer T cells (NKT cells) modified to target mesothelin, a protein prevalent on pancreatic cancer cells. This dual-action therapy attacks tumors from multiple fronts simultaneously, improving effectiveness.
Tests in various mouse models, including primary pancreatic tumors and metastases, showed that CAR-NKT cells home in on tumors and destroy them, extending survival without the common loss of potency seen in existing treatments. Moreover, unlike personalized therapies that cost hundreds of thousands of dollars, UCLA’s therapy can be produced in bulk and stored, reducing costs per dose.
Also Read: Discover the Basics of Medical Physics Fundamentals
Overcoming Solid Tumor Barriers with Advanced Immunotherapy
Pancreatic tumors create a tough microenvironment that blocks most therapies. UCLA’s approach solves this by arming NKT cells with chimeric antigen receptors (CARs), enabling the cells to infiltrate solid tumors and sustain their cancer-fighting activity. The therapy’s ability to target metastatic sites such as the liver adds to its strength.
Dr. Lili Yang, the lead scientist of the study, said, “We’ve developed a therapy that is potent, safe, scalable and affordable. The next critical step is proving it can deliver the same results in patients.” This sentiment fuels hope for patients battling this aggressive cancer.
Also Read: The Fundamentals of Immunology System Explained
UCLA’s Immunotherapy for Pancreatic Cancer: Impact and Future Prospects
Since NKT cells naturally do not cause rejection, the therapy can be made universally—one donor’s cells can treat thousands of patients. Besides pancreatic cancer, mesothelin is present in breast, ovarian, and lung cancers, broadening the therapy’s potential applications.
Also Read: Google AI Discovers Path to Cancer Therapy
The team is now preparing for clinical trials, aiming to transform how pancreatic cancer is treated. If successful, this off-the-shelf immunotherapy could offer a scalable and widely accessible solution.
This exciting advancement presents renewed hope in the fight against a cancer type that has resisted therapeutic advances for decades. With its affordability, ready availability, and potent mechanism, UCLA’s CAR-NKT immunotherapy could redefine cancer treatment.
Additionally, to stay updated with the latest developments in STEM research, visit ENTECH Online. Basically, this is our digital magazine for science, technology, engineering, and mathematics. Further, at ENTECH Online, you’ll find a wealth of information.
Reference:
- Wang, L. (2025, November 24). UCLA scientists develop one-product-fits-all immunotherapy for pancreatic cancer. UCLA. https://newsroom.ucla.edu/releases/immunotherapy-car-nkt-pancreatic-cancer-ucla
Disclaimer: We do not intend this article/blog post to provide professional, technical, or medical advice. Therefore, please consult a healthcare professional before making any changes to your diet or lifestyle. In fact, we only use AI-generated images for illustration and decoration. Their accuracy, quality, and appropriateness can differ. So, users should avoid making decisions or assumptions based only on the text and images.
- Author
- Latest Posts
Driven by passion for leveraging technology to “Build things worth Building”. I am a Software Engineer with a background in Computer Engineering from Pune University.
Having done multiple internships and volunteering programs throughout my engineering days, I have been deeply involved in the end-to-end development lifecycle, from conceptualization and design to implementation and deployment. I have been a part and also led teams at times to national/international level hackathons. Some of those include Peerlist GenAI Hackathon and NASA Space App challenges.
My educational foundation in Computer Engineering paired with the real world hands-on experience through various ventures provided me with strong knowledge of fundamental technologies.
Continuously seeking opportunities to learn and contribute. I am eager to connect with fellow innovators and contribute to impactful projects.
